Geron Announces Presentations at the American Association for Cancer Research Annual Meeting

[at noodls] – MENLO PARK, Calif., April 9, 2013 – Geron Corporation (Nasdaq: GERN) today announced presentation of the final results from the Phase 2 study of imetelstat, the company’s first-in-class telomerase inhibitor, … more

View todays social media effects on GERN

View the latest stocks trending across Twitter. Click to view dashboard

See who Geron is hiring next, click here to view